[go: up one dir, main page]

US20080021214A1 - Novel process for the preparation of linezolid and related compounds - Google Patents

Novel process for the preparation of linezolid and related compounds Download PDF

Info

Publication number
US20080021214A1
US20080021214A1 US11/868,613 US86861307A US2008021214A1 US 20080021214 A1 US20080021214 A1 US 20080021214A1 US 86861307 A US86861307 A US 86861307A US 2008021214 A1 US2008021214 A1 US 2008021214A1
Authority
US
United States
Prior art keywords
formula
fluoro
morpholinyl
phenyl
linezolid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/868,613
Inventor
Dodda Rao
Pingili Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symed Labs Ltd
Original Assignee
Symed Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35150400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080021214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symed Labs Ltd filed Critical Symed Labs Ltd
Priority to US11/868,613 priority Critical patent/US20080021214A1/en
Assigned to SYMED LABS LIMITED reassignment SYMED LABS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KRISHNA REDDY, PINGILI, MOHAN RAO, DODDA
Publication of US20080021214A1 publication Critical patent/US20080021214A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention provides a novel process for preparation of 5-aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials.
  • U.S. Pat. No. 5,688,792 U.S. Pat. No. 5,688,792
  • the compounds are antimicrobial agents.
  • linezolid chemically N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide is the most important antibacterial agent.
  • Linezolid is represented by the following structure:
  • the 5-hydroxymethyl substituted oxazolidinones are converted to the corresponding 5-aminomethyl substituted oxazolidinones, key intermediates in the production of oxazolidinone antibacterial pharmaceuticals.
  • WO 95/07271 uses butyl lithium at very low temperature ( ⁇ 78° C.) and WO 99/24393 uses phosgene gas. It is known that the handling of butyl lithium and phosgene gas are difficult and the person skilled in the art appreciate a process that produces the product in good yield avoiding the ‘difficult to handle’ reagents.
  • the present invention provides a novel process to prepare 5-aminomethyl substituted oxazolidinones of formula I: wherein
  • X is O, S, SO or SO 2 ;
  • R 1 is H, CH 3 or CN
  • R 2 is independently H, F or Cl
  • R 3 is H or CH 3 ;
  • n 0, 1 or 2;
  • R 1 , R 3 , X, R 2 and n are as defined in formula I;
  • R 1 , R 3 , X, R 2 and n are as defined in formula I;
  • the compounds of formula IV are novel and provides another aspect of the present invention.
  • the present invention provides a novel process for preparing 5-aminomethyl substituted oxazolidinones of formula I: wherein
  • X is O, S, SO or SO 2 ;
  • R 1 is H, CH 3 or CN
  • R 2 is independently H, F or Cl
  • R 3 is H or CH 3 ;
  • n 0,1 or 2.
  • R 1 , R 3 , X, R 2 and n are as defined in formula I;
  • R 1 , R 3 , X, R 2 and n are as defined in formula I.
  • the quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of phenyl amine of formula II.
  • the reaction may be carried out with or without using a solvent.
  • the compounds of formula II and the formula III are usually heated together for sufficient time to obtain the compound of formula IV.
  • the reactants are heated preferably to about 40-150° C. and more preferably to about 40-120° C.
  • the time required for the conversion is 30 minutes to 10 hours, preferably 2 to 6 hours.
  • the reaction between the compounds of formula II and formula III is carried out in a solvent.
  • Any solvent, which is neutral towards the reactants, may be used.
  • Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N,N-dimethylformamide and N,N-dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol; and a mixture thereof.
  • Preferable solvent is selected from methanol, isopropyl alcohol and N,N-dimethylformamide.
  • the reaction is performed at or below boiling temperature of the solvent used, more preferably between 10° C. and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried.
  • the product obtained may be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step.
  • the compounds of formula IV are novel and provides another aspect of the present invention.
  • the carbonylation is performed using any carbonylating reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyidiimidazole being more preferred.
  • the carbonylation reaction is preferably performed by contacting the chlorohydrin compound of formula IV with carbonylating agent in the presence of an aprotic solvent or a mixture thereof. More preferably the chlorohydrin compound of formula IV is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • Preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R 1 ⁇ R 3 is H; R 2 is independently H and F; X is O or S; and n is 1. More preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R 1 ⁇ R 3 is H; R 2 is independently H and F; X is O; and n is 1. Still more preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R 1 ⁇ R 3 is H; one R 2 is H and the other R 2 is F; X is O; and n is 1.
  • the conversion of the compound of formula V to the compound of formula I can be achieved by a method known for the conversion of aliphatic chloride to the corresponding amine.
  • chlorine atom of the chloromethyl oxazolidinone compound is first replaced by azide using azide source such as sodium azide or potassium azide to provide azide compound of formula VI:
  • R 1 , R 3 , X, R 2 and n are as defined in formula I.
  • the azide compound is known and can be converted to the aminomethyl oxazolidinone compound by known methods such as those described in U.S. Pat. No. 5,688,792.
  • the azide compound is hydrogenated using for example palladium/carbon catalyst to provide the aminomethyl oxazolidinone compound.
  • R 1 , R 3 , X, R 2 and n are as defined in formula I.
  • the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in a solvent or mixture of solvents.
  • solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction.
  • the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide.
  • the preferable solvent is dimethyl formamide or acetonitrile.
  • the reaction is performed preferably between about 10° C. and the boiling temperature of the solvent used, more preferably between 40° C. and 100° C. and most preferably at the boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 2 to 10 hours is required for the reaction completion.
  • the phthalimido compounds of formula are known and can be converted to the aminomethyl oxazolidinone compounds by using for example Hydrazine hydrate or aqueous methylamine. These methods are known and are described for example in U.S. Pat. No. 5,688,792.
  • aminomethyl oxazolidinone compounds of formula I are acylated by known methods using acylating agents such as acyl halides or acyl anhydrides to form the corresponding 5-acylaminomethyloxazolidinone compounds of formula VIII.
  • R 1 , R 3 , X, R 2 and n are as defined in formula I;
  • R represents C 1 to C 8 straight or branched alkyl groups.
  • the preferred alkyl group is CH 3 .
  • the acylation can be carried out by known methods such as those described in U.S. Pat. No. 5,688,792.
  • One compound of formula VIII can be converted to another compound of formula VIII.
  • compounds of formula VIII, wherein X is S can be converted to the compounds of formula VIII, wherein X is SO or SO 2 by the methods such as those disclosed in U.S. Pat. No. 5,688,792.
  • the 5-acyl amino methyl substituted oxazolidinone of formula VIII are known to be antibacterial pharmaceutical agents.
  • R-Epichlorohydrin has the right configuration to obtain the compounds of formula I and VIII.
  • the configuration of epichlorohydrine is retained through out the sequence of reactions of the invention.
  • linezolid (VIII, R 1 and R 3 is H; X is O, one R 2 is H and the other R 2 is F; n is 1).
  • the most preferred process for preparing linezolid is described as under:
  • the quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of 3-fluoro-4-morpholinyl aniline.
  • Any solvent, which is neutral towards the reactants, may be used.
  • Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N,N-dimethylformamide and N,N-dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol.
  • Preferable solvent is selected from methanol, isopropyl alcohol and N,N-dimethylformamide.
  • the reaction is performed at or below boiling temperature of the solvent used, more preferably between 10° C. and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried. For example, if the reaction is carried out in isopropyl alcohol solvent at the boiling temperature of the solvent, about 15 hours is required for the reaction completion.
  • the product obtained can be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step.
  • the carbonylation is performed using any carbonylating reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyldiimidazole being more preferred.
  • the carbonylation reaction is preferably performed by contacting the N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline with carbonylating agent in the presence of an aprotic solvent or a mixture of aprotic solvents. More preferably the N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • the reaction is carried out by contacting the (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone with potassium phthalimide in a solvent or a mixture of solvents.
  • solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction.
  • the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide.
  • the preferable solvent is dimethyl formamide or acetonitrile.
  • the reaction is performed preferably between about 10° C. and the boiling temperature of the solvent used, more preferably between 40° C. and 100° C. and most preferably at the boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 3 to 7 hours is required for the reaction completion.
  • 3-Fluoro-4-morpholinyl aniline (39 g) is mixed with R-epichlorohydrin (18.5 g), isopropyl alcohol (200 ml) is added and heated for 16 hours at reflux temperature. The solvent is distilled to give 57 gm of N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline.
  • N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline (57 g) is dissolved in methylene dichloride (600 ml), diimidazolyl carbonyl (32 g) is added at ambient temperature and the reaction mixture is stirred for 20 hours. Then washed with water and distilled methylene dichloride to give 48 gm of (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone.
  • reaction mixture is then cooled to 0-5° C., filtered the solid and re-crystallized from Isopropyl alcohol (400 ml) to give 16 gm of N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention provides a novel process for preparation of 5-aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials including linezolid. Thus linezolid is prepared by a) reacting 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin; b) subjecting N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline produced above to carbonylation; c) reacting (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone produced above with potassium phthalimide; d) reacting (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide produced above with hydrazine hydrate; and e) reacting S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine produced above with acetic anhydride to produce linezolid.

Description

    FIELD OF THE INVENTION
  • The present invention provides a novel process for preparation of 5-aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials.
    • BACKGROUND OF THE INVENTION
  • U.S. Pat. No. 5,688,792 (U.S. Pat. No. 5,688,792) disclosed oxazine and thiazine oxazolidinone derivatives. The compounds are antimicrobial agents. Among them linezolid, chemically N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide is the most important antibacterial agent. Linezolid is represented by the following structure:
    Figure US20080021214A1-20080124-C00001
  • Processes for preparation of linezolid were described in U.S. Pat. No. 5,837,870, WO 99/24393, WO 95/07271, J.Med.Chem. 39(3), 673-679, 1996 and Tetrahedron Lett., 40(26), 4855, 1999.
  • According to prior art processes, the 5-hydroxymethyl substituted oxazolidinones are converted to the corresponding 5-aminomethyl substituted oxazolidinones, key intermediates in the production of oxazolidinone antibacterial pharmaceuticals.
  • The prior art processes for preparing 5-aminomethyl substituted oxazolidinones are associated with many drawbacks. For instant in the preparation of linezolid, WO 95/07271 uses butyl lithium at very low temperature (−78° C.) and WO 99/24393 uses phosgene gas. It is known that the handling of butyl lithium and phosgene gas are difficult and the person skilled in the art appreciate a process that produces the product in good yield avoiding the ‘difficult to handle’ reagents.
  • We have discovered a novel process for preparation of 5-aminomethyl substituted oxazolidinone key intermediates using novel intermediates. The novel process solve the drawbacks associated with the prior processes and so, commercially viable for preparing these and related compounds.
    • SUMMARY OF INVENTION
  • The present invention provides a novel process to prepare 5-aminomethyl substituted oxazolidinones of formula I:
    Figure US20080021214A1-20080124-C00002
    wherein
  • X is O, S, SO or SO2;
  • R1 is H, CH3or CN;
  • R2 is independently H, F or Cl;
  • R3 is H or CH3;
  • n is 0, 1 or 2;
  • which comprises;
    • a) reacting a compound of formula II:
      Figure US20080021214A1-20080124-C00003
      wherein R1, R3, X, R2 and n are as defined in formula I;
    • with R-epichlorohydrin of formula III:
      Figure US20080021214A1-20080124-C00004
  • to produce a compound of formula IV:
    Figure US20080021214A1-20080124-C00005
  • wherein R1, R3, X, R2 and n are as defined in formula I;
    • b) converting the product of step (a) to chloromethyl oxazolidinone compound of formula V:
      Figure US20080021214A1-20080124-C00006
  • wherein R1, R3, X, R2 and n are as defined in formula I; and
    • c) converting the chloromethyl oxazolidinone compound of step (b) to aminomethyl oxazolidinone of formula I.
  • The compounds of formula IV are novel and provides another aspect of the present invention.
  • The compounds of the formula V with the exception of the compound of formula V wherein R1═R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1 are novel.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a novel process for preparing 5-aminomethyl substituted oxazolidinones of formula I:
    Figure US20080021214A1-20080124-C00007
    wherein
  • X is O, S, SO or SO2;
  • R1 is H, CH3 or CN;
  • R2 is independently H, F or Cl;
  • R3 is H or CH3;
  • n is 0,1 or 2.
    • Step—a) Phenyl amine compound of formula II:
      Figure US20080021214A1-20080124-C00008
  • wherein R1, R3, X, R2 and n are as defined in formula I;
  • is reacted with R-epichlorohydrin of formula III:
    Figure US20080021214A1-20080124-C00009
  • to provide chlorohydrin compound of formula IV:
    Figure US20080021214A1-20080124-C00010
  • wherein R1, R3, X, R2 and n are as defined in formula I.
  • The quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of phenyl amine of formula II.
  • The reaction may be carried out with or without using a solvent.
  • If the reaction is carried out in the absence of solvent, the compounds of formula II and the formula III are usually heated together for sufficient time to obtain the compound of formula IV. The reactants are heated preferably to about 40-150° C. and more preferably to about 40-120° C. The time required for the conversion is 30 minutes to 10 hours, preferably 2 to 6 hours.
  • Preferably, the reaction between the compounds of formula II and formula III is carried out in a solvent. Any solvent, which is neutral towards the reactants, may be used. Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N,N-dimethylformamide and N,N-dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol; and a mixture thereof. Preferable solvent is selected from methanol, isopropyl alcohol and N,N-dimethylformamide.
  • The reaction is performed at or below boiling temperature of the solvent used, more preferably between 10° C. and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried.
  • The product obtained may be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step.
  • The compounds of formula IV are novel and provides another aspect of the present invention.
    • Step—b) The chlorohydrin compound of formula IV produced as above is subjected to carbonylation to provide chloromethyl oxazolidinone compound of formula V:
      Figure US20080021214A1-20080124-C00011
      wherein R1, R3, X, R2 and n are as defined in formula I.
  • The carbonylation is performed using any carbonylating reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyidiimidazole being more preferred.
  • The carbonylation reaction is preferably performed by contacting the chlorohydrin compound of formula IV with carbonylating agent in the presence of an aprotic solvent or a mixture thereof. More preferably the chlorohydrin compound of formula IV is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • The compound of formula V wherein R1═R3 is H; X is O; one R2 is H and the other R2 is F; n is 1 ((5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone) is mentioned in the J. Pharmaceutical and biomedical analysis, 2002, 30 (3), 635-642 as an possible impurity in linezolid. We disclosed the use of this compound and related compounds in the preparation of the compounds of formula I.
  • The compounds of formula V, wherein X, R1, R2, R3 and n are as defined in formula I with the exception of the compound of formula V, wherein R1═R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1 are novel and provide another aspect of present invention.
    • Step—c) The chloromethyl oxazolidinone compound of formula V produced as above is converted to aminomethyl oxazolidinone compound of formula I.
  • Preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R1═R3 is H; R2 is independently H and F; X is O or S; and n is 1. More preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R1═R3 is H; R2 is independently H and F; X is O; and n is 1. Still more preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R1═R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1.
  • The conversion of the compound of formula V to the compound of formula I can be achieved by a method known for the conversion of aliphatic chloride to the corresponding amine.
  • Thus, for example, chlorine atom of the chloromethyl oxazolidinone compound is first replaced by azide using azide source such as sodium azide or potassium azide to provide azide compound of formula VI:
    Figure US20080021214A1-20080124-C00012
  • wherein R1, R3, X, R2 and n are as defined in formula I.
  • The azide compound is known and can be converted to the aminomethyl oxazolidinone compound by known methods such as those described in U.S. Pat. No. 5,688,792. For example, the azide compound is hydrogenated using for example palladium/carbon catalyst to provide the aminomethyl oxazolidinone compound.
  • Alternatively, the chloromethyl oxazolidinone compound is reacted with potassium phthalimide to provide phthalimido compound of formula VII:
    Figure US20080021214A1-20080124-C00013
  • wherein R1, R3, X, R2 and n are as defined in formula I.
  • The reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in a solvent or mixture of solvents. Selection of solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction. However, the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide. The preferable solvent is dimethyl formamide or acetonitrile.
  • The reaction is performed preferably between about 10° C. and the boiling temperature of the solvent used, more preferably between 40° C. and 100° C. and most preferably at the boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 2 to 10 hours is required for the reaction completion.
  • The phthalimido compounds of formula are known and can be converted to the aminomethyl oxazolidinone compounds by using for example Hydrazine hydrate or aqueous methylamine. These methods are known and are described for example in U.S. Pat. No. 5,688,792.
  • The aminomethyl oxazolidinone compounds of formula I are acylated by known methods using acylating agents such as acyl halides or acyl anhydrides to form the corresponding 5-acylaminomethyloxazolidinone compounds of formula VIII.
    Figure US20080021214A1-20080124-C00014
  • wherein R1, R3, X, R2 and n are as defined in formula I; R represents C1 to C8 straight or branched alkyl groups. The preferred alkyl group is CH3.
  • The acylation can be carried out by known methods such as those described in U.S. Pat. No. 5,688,792.
  • One compound of formula VIII can be converted to another compound of formula VIII. Thus for example compounds of formula VIII, wherein X is S can be converted to the compounds of formula VIII, wherein X is SO or SO2 by the methods such as those disclosed in U.S. Pat. No. 5,688,792.
  • The 5-acyl amino methyl substituted oxazolidinone of formula VIII are known to be antibacterial pharmaceutical agents.
  • R-Epichlorohydrin has the right configuration to obtain the compounds of formula I and VIII. The configuration of epichlorohydrine is retained through out the sequence of reactions of the invention. However, it is readily apparent to one skilled in the art that one could easily perform the identical process steps with the opposite enantiomeric form or racemic form to obtain the corresponding stereo isomers.
  • Therefore, using the chemistry of the claimed process with any of the enantiomeric forms is considered equivalent to the claimed processes.
  • In particular most important compound of formula VIII is linezolid (VIII, R1 and R3 is H; X is O, one R2 is H and the other R2is F; n is 1). The most preferred process for preparing linezolid is described as under:
    • a) 3-fluoro-4-morpholinyl aniline (formula II, R1═R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1) is reacted with R-epichlorohydrin (formula III) to produce N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline (formula IV, R1═R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1);
  • The quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of 3-fluoro-4-morpholinyl aniline.
  • Any solvent, which is neutral towards the reactants, may be used. Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N,N-dimethylformamide and N,N-dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol. Preferable solvent is selected from methanol, isopropyl alcohol and N,N-dimethylformamide.
  • The reaction is performed at or below boiling temperature of the solvent used, more preferably between 10° C. and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried. For example, if the reaction is carried out in isopropyl alcohol solvent at the boiling temperature of the solvent, about 15 hours is required for the reaction completion.
  • The product obtained can be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step.
    • b) N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline produced as above is subjected to carbonylation to provide (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone (Formula V, R1═R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1).
  • The carbonylation is performed using any carbonylating reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyldiimidazole being more preferred.
  • The carbonylation reaction is preferably performed by contacting the N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline with carbonylating agent in the presence of an aprotic solvent or a mixture of aprotic solvents. More preferably the N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
    • c) (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone produced as above is reacted with potassium phthalimide to provide (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide (Formula VII, R1═R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1);
  • The reaction is carried out by contacting the (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone with potassium phthalimide in a solvent or a mixture of solvents. Selection of solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction. However, the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide. The preferable solvent is dimethyl formamide or acetonitrile.
  • The reaction is performed preferably between about 10° C. and the boiling temperature of the solvent used, more preferably between 40° C. and 100° C. and most preferably at the boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 3 to 7 hours is required for the reaction completion.
    • d) (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide produced as above is reacted with hydrazine hydrate or aqueous methyl amine to produce S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine (Formula I, R1═R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1). These methods of deprotection are known and described for example in U.S. Pat. No. 5,688,792.
    • e) S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine is reacted with acetic anhydride to produce linezolid.
  • The following examples are given for the purpose of illustrating the present invention and should not be considered as limitations on the scope and spirit of the invention.
    • EXAMPLES Example 1
  • 3-Fluoro-4-morpholinyl aniline (39 g) is mixed with R-epichlorohydrin (18.5 g), isopropyl alcohol (200 ml) is added and heated for 16 hours at reflux temperature. The solvent is distilled to give 57 gm of N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline.
    • Example 2
  • N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline (57 g) is dissolved in methylene dichloride (600 ml), diimidazolyl carbonyl (32 g) is added at ambient temperature and the reaction mixture is stirred for 20 hours. Then washed with water and distilled methylene dichloride to give 48 gm of (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone.
    • Example 3
  • The mixture of (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone (60 g), potassium phthalimide (40 g) and Dimethyl formamide (400 ml) is heated for 5 hours at reflux temperature. The reaction mixture is cooled to ambient temperature, poured in to 2 L water and filtered the solid to give 50 gm (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide.
    • Example 4
  • Methanol (240 ml) and Hydrazine hydrate (26 g) are added to a flask containing the (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide (40 g), heated for 1 hour at reflux temperature and cooled to room temperature. Then water (500 ml) is added to the reaction mass and extracted with methylene dichloride (300 ml). The combined extractions were washed with water (100 ml) and the solvent distilled to give 20 gm of S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine.
    • Example 5
  • S-N-[[3-[3-Fluoro4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine (20 gm) is dissolved in Ethyl acetate (200 ml), Acetic anhydride (20 gm) is added drop wise at ambient temperature and stirred for 1 hour. The reaction mixture is then cooled to 0-5° C., filtered the solid and re-crystallized from Isopropyl alcohol (400 ml) to give 16 gm of N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

Claims (2)

1-57. (canceled)
58. A compound of formula V:
Figure US20080021214A1-20080124-C00015
wherein
X is O, S, SO or SO2;
R1 is H, CH3 or CN;
R2 is independently H, F or Cl;
R3 is H or CH3;
n is 0, 1 or 2;
with the exception of the compound or formula V, wherein R1═R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1.
US11/868,613 2004-04-19 2007-10-08 Novel process for the preparation of linezolid and related compounds Abandoned US20080021214A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/868,613 US20080021214A1 (en) 2004-04-19 2007-10-08 Novel process for the preparation of linezolid and related compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IN2004/000105 WO2005099353A2 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds
US10/524,746 US7307163B2 (en) 2004-04-19 2004-04-19 Process for the preparation of linezolid and related compounds
US11/868,613 US20080021214A1 (en) 2004-04-19 2007-10-08 Novel process for the preparation of linezolid and related compounds

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/524,746 Division US7307163B2 (en) 2004-04-19 2004-04-19 Process for the preparation of linezolid and related compounds
PCT/IN2004/000105 Division WO2005099353A2 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds

Publications (1)

Publication Number Publication Date
US20080021214A1 true US20080021214A1 (en) 2008-01-24

Family

ID=35150400

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/524,746 Expired - Lifetime US7307163B2 (en) 2004-04-19 2004-04-19 Process for the preparation of linezolid and related compounds
US11/868,613 Abandoned US20080021214A1 (en) 2004-04-19 2007-10-08 Novel process for the preparation of linezolid and related compounds
US11/868,633 Expired - Fee Related US7741480B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,608 Expired - Lifetime US7351824B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,662 Expired - Lifetime US7524954B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/524,746 Expired - Lifetime US7307163B2 (en) 2004-04-19 2004-04-19 Process for the preparation of linezolid and related compounds

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/868,633 Expired - Fee Related US7741480B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,608 Expired - Lifetime US7351824B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,662 Expired - Lifetime US7524954B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds

Country Status (6)

Country Link
US (5) US7307163B2 (en)
EP (1) EP1737850B1 (en)
DE (1) DE602004009344T2 (en)
ES (1) ES2294494T3 (en)
PL (1) PL1737850T3 (en)
WO (1) WO2005099353A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180253272A1 (en) * 2017-03-02 2018-09-06 Fuji Xerox Co., Ltd. Information processing device and non-transitory medium
US10284923B2 (en) 2007-10-24 2019-05-07 Lifesignals, Inc. Low power radiofrequency (RF) communication systems for secure wireless patch initialization and methods of use

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035530A1 (en) 2003-10-16 2005-04-21 Symed Labs Limited A novel crystalline form of linezolid
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
ATE429423T1 (en) * 2004-07-20 2009-05-15 Symed Labs Ltd NEW INTERMEDIATE PRODUCTS FOR LINEZOLID AND RELATED COMPOUNDS
WO2007140439A2 (en) 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
BRPI0712720A2 (en) 2006-05-31 2012-11-20 Abbott Lab thiazide compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2142522A1 (en) 2007-03-28 2010-01-13 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
MX2009012374A (en) 2007-05-18 2009-12-01 Abbott Lab Novel compounds as cannabinoid receptor ligands.
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
TW200942535A (en) 2008-03-11 2009-10-16 Abbott Lab Novel compounds as cannabinoid receptor ligands
CN102083797B (en) 2008-04-01 2014-06-04 Abbvie公司 Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy
CN102123993A (en) 2008-08-15 2011-07-13 雅培制药有限公司 Imine derivatives as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8859596B2 (en) 2008-09-16 2014-10-14 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8609692B2 (en) 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
TW201020236A (en) 2008-10-17 2010-06-01 Abbott Lab TRPV1 antagonists
UA108193C2 (en) 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ME02642B (en) 2008-12-05 2017-06-20 Abbvie Inc Sulfonamide derivatives as bcl- 2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PA8854001A1 (en) 2008-12-16 2010-07-27 Abbott Lab NEW COMPOUNDS AS CANABINOID RECEIVERS LIGANDS
CN101774978B (en) 2009-01-13 2011-09-21 联化科技股份有限公司 Preparation method of linezolid and intermediate thereof
EP2511264B1 (en) 2009-01-19 2015-03-11 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2747837A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
TWI519530B (en) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 Carboxamide compounds and their use as calpain inhibitors
WO2010111572A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2411371B1 (en) 2009-03-27 2015-05-20 AbbVie Inc. Compounds as cannabinoid receptor ligands
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PT2435432E (en) 2009-05-26 2015-10-13 Abbvie Bahamas Ltd APOPTOSE INDUCTIVE AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMUNE DISEASES
US8962639B2 (en) 2009-05-29 2015-02-24 Abbvie Inc. Potassium channel modulators
US20110095033A1 (en) 2009-10-28 2011-04-28 Belkin International, Inc. Portable Multi-Media Communication Device Protective Carrier and Method of Manufacture Therefor
MX2012006036A (en) 2009-11-25 2012-06-19 Abbott Lab Potassium channel modulators.
TW201130855A (en) 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
US20130137864A1 (en) 2009-12-26 2013-05-30 Jayaraman Venkat Raman Process for the preparation of linezolid
SI2550258T1 (en) 2010-03-25 2016-01-29 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5865898B2 (en) 2010-04-30 2016-02-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Process for preparing linezolid
TWI520960B (en) 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2012019315A1 (en) 2010-08-10 2012-02-16 Abbott Laboratories Novel trpv3 modulators
EP2603506A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
CN103140487A (en) 2010-08-11 2013-06-05 斯索恩有限公司 Process for making linezolid
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US20130172554A1 (en) * 2010-09-07 2013-07-04 Symed Labs Limited Processes for the preparation of 4-morpholin-3-one
JP5998142B2 (en) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
RU2598345C2 (en) 2010-10-29 2016-09-20 Эббви Инк. Solid dispersions containing agents causing apoptosis
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CA2817093A1 (en) 2010-11-15 2012-05-24 Abbvie Inc. Nampt inhibitors
RU2013126657A (en) 2010-11-15 2014-12-27 Эббви Инк. NAMPT AND ROCK INHIBITORS
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
TWI535701B (en) 2010-11-23 2016-06-01 艾伯維巴哈馬有限公司 Methods of treatment using selective bcl-2 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9567307B2 (en) * 2011-01-07 2017-02-14 The Regents Of The University Of California Amination of aryl alcohol derivatives
HUE027158T2 (en) * 2011-02-24 2016-08-29 Lee Pharma Ltd Novel process for preparation of linezolid and its novel intermediates
CN102174043B (en) * 2011-02-28 2013-11-13 石药集团中诺药业（石家庄）有限公司 Method for preparing linezolid intermediate
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
TW201302681A (en) 2011-03-25 2013-01-16 Abbott Lab TRPV1 antagonists
US9221771B2 (en) 2011-04-11 2015-12-29 Sandoz Ag Method for the preparation of substituted oxazolidinones
CN102229577A (en) * 2011-05-11 2011-11-02 石药集团中诺药业（石家庄）有限公司 Method for preparation and purification of Linezolid intermediate
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
MX2014001457A (en) 2011-08-05 2014-08-21 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives, pharmaceutical compositions containing them, and their use in therapy.
EP2753619A2 (en) * 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
TWI571466B (en) 2011-10-14 2017-02-21 艾伯維有限公司 Apoptosis-inducing agent for treating cancer and immune and autoimmune diseases
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8772499B2 (en) 2011-10-24 2014-07-08 Abbvie Inc. TRPV3 modulators
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103103229B (en) * 2011-11-15 2015-03-18 安琪酵母股份有限公司 Synthesis method of linezolid intermediate
CN104011028A (en) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013105100A1 (en) * 2012-01-09 2013-07-18 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN103254148B (en) 2012-02-15 2016-04-13 浙江海正药业股份有限公司 The preparation method of linezolid intermediate
CZ2012114A3 (en) 2012-02-17 2013-02-20 Zentiva, K.S. Process for preparing rivaroxaban based on saving of 1,1?-carbonyldiimidazole
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
HK1206744A1 (en) 2012-04-20 2016-01-15 Abbvie Inc. Isoindolone derivatives
CN104684906B (en) 2012-05-11 2017-06-09 艾伯维公司 Nampt inhibitor
MX2014013758A (en) 2012-05-11 2015-02-05 Abbvie Inc Thiazolecarboxamide derivatives for use as nampt inhibitors.
AR091023A1 (en) 2012-05-11 2014-12-30 Abbvie Inc NAMPT INHIBITORS
CA2873060A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
EP2858982A4 (en) 2012-06-12 2015-11-11 Abbvie Inc Pyridinone and pyridazinone derivatives
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103570639B (en) * 2012-08-08 2016-02-03 成都国弘医药有限公司 A kind of synthetic method of Linezolid
UA116216C2 (en) 2012-09-14 2018-02-26 Еббві Дойчланд Гмбх Унд Ко. Кг Tricyclic quinoline and quinoxaline derivatives
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
CN102898394A (en) * 2012-11-09 2013-01-30 重庆医科大学 Method for preparing linezolid
ES2603252T3 (en) 2012-11-09 2017-02-24 Synthon Bv Process to prepare linezolid
BR112015021549A2 (en) 2013-03-13 2017-07-18 Abbvie Inc pyridine kinase cdk9 inhibitors
BR112015023013A2 (en) 2013-03-13 2017-07-18 Abbvie Inc cdk9 kinase inhibitors
JP2016510789A (en) 2013-03-14 2016-04-11 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Oxindole derivatives bearing oxetane substituents and their use to treat vasopressin-related diseases
CA2902655A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
TW201444836A (en) 2013-03-14 2014-12-01 Abbvie Inc Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105189512A (en) 2013-03-14 2015-12-23 艾伯维公司 Pyrrolopyrimindine CDK9 kinase inhibitors
WO2014141067A2 (en) 2013-03-14 2014-09-18 Benova Labs Pvt Limited Process for the preparation of oxazolidinone derivatives
BR112015023356A2 (en) 2013-03-14 2017-07-18 Abbvie Inc pyrrol [2,3-b] pyridine cdk9 kinase inhibitors
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014170908A1 (en) * 2013-04-18 2014-10-23 Nosch Labs Private Limited Process for preparation of oxazolidinone derivatives
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336153A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
CN103864707B (en) * 2014-02-28 2015-11-04 烟台万润药业有限公司 (S)-[3-(the fluoro-4-morpholinyl of 3-) phenyl-2-oxo-5-oxazolidinyl] methylamine preparation method
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016160938A1 (en) 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
CN105111160B (en) * 2015-09-11 2017-04-12 浙江新东港药业股份有限公司 Linezolid preparation method
WO2017089458A1 (en) 2015-11-25 2017-06-01 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
US10835535B2 (en) 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
PT3612531T (en) 2017-04-18 2022-10-04 Shanghai Fochon Pharmaceutical Co Ltd Apoptosis-inducing agents
BR112020018444A2 (en) 2018-03-14 2020-12-29 Fochon Pharmaceuticals, Ltd. (2-AZABICYCLE [3,1,0] HEXAN-2-IL) COMPOUNDS PIRAZOLO [1,5-A] REPLACED PYRIMIDINE AND IMIDAZO [1,2-B] PYRIDAZINE AS TRK KINASE INHIBITORS
AU2019236892B2 (en) 2018-03-23 2023-12-14 Fochon Pharmaceuticals, Ltd. Deuterated compounds as ROCK inhibitors
WO2021184339A1 (en) 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
CN115925647A (en) * 2022-12-26 2023-04-07 湖北广济药业股份有限公司 Production method of linezolid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029786A (en) * 1972-08-11 1977-06-14 Imperial Chemical Industries Limited Morpholine derivatives for treating depression
DE2810349A1 (en) 1978-03-10 1979-09-20 Kali Chemie Pharma Gmbh PROCESS FOR THE PREPARATION OF 3-HYDROXY-6-PHENYL-1,2,3,4-TETRAHYDRO-1,5-BENZODIAZOCINES
FR2506769A2 (en) 1978-06-09 1982-12-03 Delalande Sa Cyano:pentyl:phenyl-methoxymethyl-oxazolidinone - useful as antidepressant
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2608604B1 (en) 1986-12-19 1989-04-28 Delalande Sa 5-HYDROXYETHYL DERIVATIVES OF OXAZOLIDINONE-2, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH09278722A (en) * 1996-02-09 1997-10-28 Pola Chem Ind Inc Optically active propanol derivative
ES2166073T3 (en) * 1996-04-11 2002-04-01 Upjohn Co PROCEDURE TO PREPARE OXAZOLIDINONES.
SK286569B6 (en) 1997-11-07 2009-01-07 Pharmacia & Upjohn Company Method for the production of oxazolidinones
US6605732B1 (en) * 1999-05-03 2003-08-12 Aerojet Fine Chemicals Llc Clean, high-yield preparation of S,S and R,S amino acid isosteres
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
AR027261A1 (en) 2000-02-02 2003-03-19 Upjohn Co LINEZOLID CRYSTAL FORM II
MY127336A (en) 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
PT1783118E (en) 2000-08-14 2008-08-19 Teva Pharma Preparation of risperidone
WO2002085849A2 (en) 2001-04-20 2002-10-31 Pharmacia & Upjohn Company Process to prepare oxazolidinones
CN1155585C (en) 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3, 5-substituted oxazolidinone derivative and preparation method and application thereof
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
WO2005035530A1 (en) 2003-10-16 2005-04-21 Symed Labs Limited A novel crystalline form of linezolid
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
CA2572054A1 (en) 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid
ATE429423T1 (en) * 2004-07-20 2009-05-15 Symed Labs Ltd NEW INTERMEDIATE PRODUCTS FOR LINEZOLID AND RELATED COMPOUNDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10284923B2 (en) 2007-10-24 2019-05-07 Lifesignals, Inc. Low power radiofrequency (RF) communication systems for secure wireless patch initialization and methods of use
US20180253272A1 (en) * 2017-03-02 2018-09-06 Fuji Xerox Co., Ltd. Information processing device and non-transitory medium

Also Published As

Publication number Publication date
PL1737850T3 (en) 2008-02-29
US20080021213A1 (en) 2008-01-24
EP1737850B1 (en) 2007-10-03
US7307163B2 (en) 2007-12-11
WO2005099353A2 (en) 2005-10-27
US7524954B2 (en) 2009-04-28
WO2005099353A3 (en) 2006-10-26
US20070032472A1 (en) 2007-02-08
DE602004009344D1 (en) 2007-11-15
EP1737850A2 (en) 2007-01-03
US20080021215A1 (en) 2008-01-24
US20080027219A1 (en) 2008-01-31
US7351824B2 (en) 2008-04-01
ES2294494T3 (en) 2008-04-01
US7741480B2 (en) 2010-06-22
DE602004009344T2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US7351824B2 (en) Process for the preparation of linezolid and related compounds
US7429661B2 (en) Intermediates for linezolid and related compounds
US6362334B1 (en) Phthalamide compounds
US8106192B2 (en) Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
EP1328509B1 (en) Methods of producing oxazolidinone compounds
US20080091011A1 (en) Novel crystalline form of linezolid
US20130172554A1 (en) Processes for the preparation of 4-morpholin-3-one
EP3060559A2 (en) Improved process for the preparation of ((3s,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methyl-4-methylbenzenesulfonate
WO2013046211A1 (en) Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
US7217726B2 (en) Antibacterial agents
EP3095777B1 (en) Linezolid intermediate and method for synthesizing linezolid
CA2614105A1 (en) Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents
US20070167414A1 (en) Novel antibacterial agents
CN1044473C (en) Tropone-substituted phenyloxazolidinone antibacterial agents
JP6948693B2 (en) Method for Producing Azilsartan Synthetic Intermediate
WO2017182853A1 (en) An improved process for the preparation of linezolid

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYMED LABS LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOHAN RAO, DODDA;KRISHNA REDDY, PINGILI;REEL/FRAME:020194/0794

Effective date: 20050510

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION